Save Product
Product Details
Synonyms
Spike, S protein, Spike glycoprotein, S glycoprotein
Source
SARS-CoV-2 Spike Trimer, His Tag (B.1.1.529/Omicron) (SPN-C52Hz) is the ectodomain of SARS-CoV-2 spike protein which contains AA Val 16 - Pro 1213 (Accession # QHD43416.1 (A67V, HV69-70del, T95I, G142D, VYY143-145del, N211del, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F)). The 35 spike mutations are identified on the SARS-CoV-2 Omicron variant (Pango lineage: B.1.1.529; GISAID clade: GR/484A; Nextstrain clade: 21K). The recombinant protein is expressed from human 293 cells (HEK293) with T4 fibritin trimerization motif and a polyhistidine tag at the C-terminus. Proline substitutions (F817P, A892P, A899P, A942P, K986P, V987P) and alanine substitutions (R683A and R685A) are introduced to stabilize the trimeric prefusion state of SARS-CoV-2 S protein and abolish the furin cleavage site, respectively.
Predicted N-terminus: Val 16
Request for sequenceMolecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 138.2 kDa. The protein migrates as 160-190 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in 0.1 M Sodium citrate, pH5.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
SARS-CoV-2 Spike Trimer, His Tag (B.1.1.529/Omicron) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
SEC-MALS
The purity of SARS-CoV-2 Spike Trimer, His Tag (B.1.1.529/Omicron) (Cat. No. SPN-C52Hz) is more than 90% and the molecular weight of this protein is around 525-605 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized SARS-CoV-2 Spike Trimer, His Tag (B.1.1.529/Omicron) (Cat. No. SPN-C52Hz) at 1 μg/mL (100 μL/well) can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.4-50 ng/mL (QC tested).
Protocol
Immobilized SARS-CoV-2 Spike Trimer, His Tag (B.1.1.529/Omicron) (Cat. No. SPN-C52Hz) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) with a linear range of 0.4-50 ng/mL (Routinely tested).
Protocol
Immobilized SARS-CoV-2 Spike Trimer, His Tag (B.1.1.529/Omicron) (Cat. No. SPN-C52Hz) at 1 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (Omicron Specific) (Cat. No. SPD-M305) with a linear range of 0.5-8 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
M***g2022-05-07
LikesThis product was purchased to conduct plasma screens for anti-SARS-CoV-2 antibodies and perform antibody monoclonal antibody binding/capture studies on BLI. This product came out in a timely manner following its designation as a VOC and was delivered quickly. The protein produced high quality and consistent results in both MSD and BLI experiments and is remarkably stable at 4C where it was stored for approximately 3 weeks without any appreciable change in experimental result.
Background
Recent Advances
Drug Development Progress- English Name：
Coronavirus spike glycoprotein
- Category：
- Approved Drugs：
15 Details
- Drugs in Clinical Trials：
88 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
